Theravance
Theravance Biopharma.: Home.
Launch date
Employees
Market cap
€362m
Enterprise valuation
€317m (Public information from Sep 2024)
Share price
$8.01 TBPH
San Francisco California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 71.9m | 55.3m | 51.3m | 57.4m | 70.6m | 96.0m | 118m |
% growth | (2 %) | (23 %) | (7 %) | 12 % | 23 % | 36 % | 22 % |
EBITDA | (226m) | (133m) | (70.6m) | (40.3m) | - | - | - |
% EBITDA margin | (315 %) | (240 %) | (137 %) | (70 %) | - | - | - |
Profit | (278m) | (199m) | 872m | (55.2m) | (36.0m) | 2.9m | 17.2m |
% profit margin | (387 %) | (361 %) | 1699 % | (96 %) | (51 %) | 3 % | 15 % |
EV / revenue | 20.4x | 23.7x | 9.3x | 9.8x | 5.7x | 4.2x | 3.4x |
EV / EBITDA | -6.5x | -9.9x | -6.8x | -13.9x | - | - | - |
R&D budget | 261m | 194m | 63.4m | 40.6m | - | - | - |
R&D % of revenue | 363 % | 350 % | 123 % | 71 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | N/A | IPO | |
* | N/A | $400m | Private Placement VC |
N/A | $101m | IPO | |
Total Funding | €364m |